Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive lung disease in most cases,
and effective treatment is still lacking. This review examines the current status of treatment …

Idiopathic pulmonary fibrosis (IPF) is a common form of interstitial lung disease and usually
results in progressive respiratory insufficiency and death. Steady progress has been made …

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a …

Management of idiopathic pulmonary fibrosis (IPF) has rapidly evolved in the past decade,
with 2 disease-modifying pharmacologic therapies now widely available. Despite this …

The long-standing need to determine an effective medical treatment regimen with clinically
significant and relevant end-points to improve outcome for patients with idiopathic …

Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease associated with a
high mortality rate. Novel antifibrotic therapies have been recently demonstrated to slow …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing lung disorder characterized by
progressive dyspnea, exercise intolerance and, ultimately, respiratory failure and death. The …

Idiopathic pulmonary fibrosis (IPF) represents one of the most challenging diseases for chest
physicians. The diagnostic process is complex and requires close interaction with different …

Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating, scarring lung disease
with a worse prognosis than some cancers. The incidence of IPF is increasing and while …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive parenchymal lung disease
characterized by a median survival of 3–5 years following diagnosis. The diagnosis is based …